Role of Cytogenetics and FISH in Laboratory Workup of B Cell Precursor Acute Lymphoblastic Leukemia

Abstract Modern therapeutic protocols in acute leukemias risk stratify disease based on genetic characterization of the neoplastic cells and their response to treatment. Genetic characterization is routinely performed by cytogenetic testing of leukemic cells and is a standard component of modern risk-adapted therapy in acute lymphoblastic leukemia (ALL). High-throughput technologies like RNA sequencing have identified multiple novel subtypes in recent years. The cytogenetic strategy using GTG and fluorescent in-situ hybridization (FISH) has to be adapted to identify not only the primary principal chromosomal abnormalities but also the novel subtypes. In the review, we describe a systematic comprehensive cytogenetic strategy that integrates information from immunophenotyping, flow-based DNA ploidy, and karyotyping complemented by targeted FISH studies to identify more than 70% of genetic abnormalities described in B cell precursor ALL. The simplified strategy includes a four-probe FISH and flow ploidy strategy, ± karyotyping that identifies high risk ( KMT2A, BCR::ABL1 , hypodiploidy, iAMP21) and standard risk ( ETV6::RUNX1 and high hyperdiploid) cytogenetic groups. The extended FISH panel includes probes targeting MEF2D, ZNF384 , and CRLF2 rearrangements that are used intuitively on integrating the immunophenotyping features that characterize these entities. The strategy also includes a systematic approach to identify masked hypodiploidy integrating targeted FISH analysis directed toward identifying monosomies of chromosomes 7, 15, and 17 and flow cytometry-based DNA ploidy analysis. The recently described PH-like ALL is characterized by ABL class fusions and rearrangements of CRLF2 and JAK2 genes. FISH analysis using break-apart probes can be used to identify these aberrations. The cytogenetic approach also includes FISH analysis to identify intragenic and whole gene deletions of the IKZF1 genes that identify a subset of patients associated with high risk of treatment failure.


Introduction
Modern treatment protocols in acute lymphoblastic leukemia (ALL) risk stratify patients based on genetic characteristics of leukemic cells and response to treatment. 1 Genetic characterization is routinely performed by cytogenetic testing of leukemic cells and is a standard component of modern risk-adapted therapy in ALLs. 2,3Arising from the precursors of the lymphoid lineage, ALLs are either B cell precursor (BCP-ALL) or T cell type (T-ALL).BCP-ALL accounts for 75% of ALLs in children and 80% of ALLs in adults and comprises multiple genetic subtypes defined by their sentinel finding chromosomal abnormalities that are essential in risk stratification.T-ALLs, on other hand, are treated as a high-risk disease upfront and hence this review will focus on cytogenetic characterization of BCP-ALL.

Recurring Chromosomal Alterations in BCP-ALL
BCP-ALLs are characterized by a spectrum of finding chromosomal abnormalities that occur early in the course of the disease and are prognostic and predictive of outcomes. 4opy number abnormalities and sequence mutations are cooperating secondary lesions in leukemogenesis and may either be acquired or enriched at disease progression (►Table 1). 5,6The clinically significant chromosomal abnormalities include aneuploidies and chromosomal translocations/gene rearrangements.High hyperdiploidy (HH) and ETV6::RUNX1 fusions have more than 90% cure rates and are categorized as standard risk 7,8 and TCF3::PBX1 fusions are categorized as intermediate risk.Hypodiploidy, intrachromosomal amplification of chromosome 21 (iAMP21), BCR::ABL1, TCF3::HLF1 fusions, complex karyotypes, and KMT2A rearrangements are categorized as high risk. 9he distribution of the cytogenetic subtypes is variable in different age groups with good risk cytogenetic subtypes, that is, HH and ETV6::RUNX1 fusions being more frequent in pediatric patients and BCR::ABL1 being more frequent in adults.KMT2A rearrangements are characteristic of infant ALL with prevalence rising in adults (10-15%). 9,10togenetic and Molecular Methods to Characterize BCP-ALL Karyotyping Chromosome banding technique is a morphological assessment of whole genome of a single cell and requires fresh samples and skilled manpower.The turnaround time varies from 5 to 10 days.The chromosomes are best studied at the metaphase stage of the cell cycle when the chromatin is condensed and chromosome morphology is well defined.The reliability of karyotyping analysis depends on obtaining good quality analyzable metaphases from neoplastic cells.Blasts with low proliferative potential and a proportion of HH cases may not yield analyzable metaphases, the results being interpreted erroneously as normal karyotype in such cases.Correlating FISH and flow ploidy results in these cases aids in accurately identifying the cytogenetic subtype.

Fluorescent in Situ Hybridization
Fluorescent in situ hybridization (FISH) is based on the principle of hybridization of single-stranded DNA probes labeled with fluorophores to their complementary genomic sequences.FISH does not require live cells, is relatively inexpensive, and allows transport of samples for testing at referral laboratories.FISH microscopy images can also be reviewed centrally to ensure standardization and diagnostic accuracy across treatment centers.Sensitivity varies from 1 to 5%.

Preanalytical Variables and Quality Control in Karyotyping and FISH
The first pull bone marrow aspirate sample is the preferred sample for cytogenetic studies that should be transported as soon as possible to the laboratory and processed with minimum delay.However, peripheral blood samples with high blast counts can also be utilized for FISH studies.Samples should be collected in heparin vials.
A minimum of 20 metaphases obtained from two independent cultures should be analyzed.In the presence of a clonal cytogenetic abnormality, evaluation of fewer than 20 metaphases is acceptable.
In FISH analysis, each probe should be validated for various thresholds, aberrant signal patterns to establish false positive/negative ranges.A minimum of 100 interphase nuclei by two analysts for diagnostic samples and 200 interphase nuclei for follow-up samples are recommended.The cutoff value for fusion probes is 1% and a higher cutoff for break apart probes is recommended.Cutoff values for each probe can be calculated by either using coefficient of variation with standard deviation and β inverse function or by using the Excel (Microsoft, Redmond, Washington, United States) statistical function CRITBINOM (n, p, α) with a confidence level of 95%.When results are just above the cutoff value, the report should mention that the clinical significance is unclear. 11n patients with lymphoblastic lymphoma without bone marrow involvement the cytogenetic characterization can be performed on either touch preparations, or on formalin fixed paraffin embedded sections.

Single-Nucleotide Polymorphism Array
Single-nucleotide polymorphism (SNP) arrays is a useful tool to study copy number abnormalities, polymorphisms, and copy neutral loss of heterozygosity at a whole genome level.The technology is based on the principle of hybridizing fragmented nucleic acid sequences derived from patient's DNA that are labeled with fluorescent dyes on the allelespecific oligonucleotide probes immobilized on array chip.The hybridization signal is recorded using a detection system and results are interpreted.SNP arrays can identify aneuploidies, chromosomal duplications, deletions, and copy neutral loss of heterozygosity.High-density SNP array in ALLs identifies hyperdiploidy, hypodiploidy, hidden hypodiploidy, IKZF1 deletions, and IKZF1 Plus patients (deletions in PAX5, CDKN2A, CDKN2B, PAR1 deletions with absence of ERG deletions). 12,13The utility of SNP array in routine

Transcriptome Analysis
5][16] High costs, lack of expertise in analysis of data, and limited access to the technology have restricted its wider use in routine diagnostic laboratories.

FISH-Based Strategy
We developed a cytogenetic strategy based on three probe FISH testing and flow ploidy to identify principal genetic subtypes of BCP-ALL (►Fig.1). 17The three-probe FISH strategy includes dual-color fusion probe targeting ETV6::RUNX1 fusion, dual color fusion probe targeting BCR::ABL1 fusion, and KMT2A break-apart probe.The three-probe strategy has evolved into four-probe strategy by adding the TCF3 triple color probe to identify TCF3::PBX1 and TCF3::HLF1 fusions.
FISH analysis is performed in a stepwise manner, the first step involves testing using ETV6::RUNX1 probe in pediatric ALL patients and setting up sample for karyotyping and flow based detection of DNA index/ploidy.Samples that test positive for ETV6::RUNX1 fusion are not tested using additional probes.If the sample tests negative, reflex testing is performed using BCR::ABL1 dual-color fusion probe, KMT2A break-apart probe, and TCF3 break-apart probe.Adult ALL patients are tested for BCR::ABL1 fusion in the first step.
Additional Findings Using ETV6::RUNX1 Dual-Color Fusion Probe FISH analysis using ETV6::RUNX1 dual color probe not only identifies the fusion but also identifies iAMP21 and is a screening tool to identify HH. 3,17 HH: Presence of three to four discrete additional RUNX1 signals is suggestive of HH as these patients universally gain chromosome 21.Almost 25 to 30% of HH patients show normal karyotypes.In these patients (hidden HH) presence of additional RUNX1 signals is suggestive of HH and can be confirmed by using centromeric probes targeting chromosomes 4, 10, and 17 and correlating with flow ploidy.
iAMP21: iAMP21 is defined by the presence of five or more total copies of RUNX1 in interphase cells or three or more extra RUNX1 signals on a single abnormal chromosome 21 in a tandem step ladder arrangement. 18ditional Findings Using BCR::ABL1 Dual-Color Fusion Probe FISH analysis using the dual-color fusion probe identifies BCR::ABL1 fusions and is also a screening tool to identify other ABL1 translocations.Presence of additional ABL1 signal

Cytogenetics of Acute Lymphoblastic Leukemia Dhabe et al. 485
indicates the presence of ABL1 rearrangements involving other partner genes.The ABL1 rearrangement in these patients needs to be confirmed using ABL1 break-apart probe.

Aneuploidies
The clinically relevant aneuploid entities in ALL comprises of HH, near triploidy, near-tetraploidy, near haploidy, and low hypodiploidy.HH and low hyperidiploidy are associated with intermediate prognosis.

High Hyperdiploidy
HH ALL forms one of the largest subgroups accounting for 30 to 40% of pediatric B cell ALL making it one of the most common malignancy in the pediatric population.HH ALL is characterized by non-random gains of chromosomes X,4,6,10,17,18, and 21 more frequently as trisomies followed by tetrasomies, with the modal chromosome number ranging from 51 to 67 chromosomes. 19HH ALL is generally associated with favorable clinical features like low white cell counts, age 2 to 7 years and a very low incidence of extramedullary disease. 4The outcome is superior with more than 90% overall survival in modern treatment protocols.Gains of specific chromosomes in HH ALL have been implicated as a significant factor affecting outcomes.Analyzing the cytogenetic data þ6, þ4/þ 10, þ10/þ 17, and þ4/þ 18 has been reported as good risk indicators in various studies. 4,20,21The Children's Oncology group uses the presence of triple trisomies (trisomies of chromosomes 4,10 and 17) as a good risk indicator. 22Lower modal numbers and the presence of trisomy 5 have been implicated as poor risk indicators in some studies. 20However, these associations were not found to be consistent between the various clinical trials.Nearly 50% of HH patients show structural changes duplication of long arm of chromosome 1 being most common.Fusions are rare in HH patients.Patients with BCR:: ABL1, ETV6::RUNX1 or KMT2A rearrangements may be seen along with chromosomal gains and a hyperdiploid karyotype.These gains are usually secondary and the patients are assigned to the risk subtype based on the fusions present.
Diagnosis of HH ALL: Identified by karyotyping, flow cytometric-based DNA index, and SNP array.About 25 to 30% of HH patients show normal karyotype and diagnosis is based on flow cytometric DNA index and additional RUNX1 signals on ETV6::RUNX1 FISH analysis and CEP probes targeting chromosome 4,10, and 17. 23,24 In patients with failed karyotype result, gain of RUNX1 signals on ETV6::RUNX1 FISH analysis suggests presence of HH, and the diagnosis is to be confirmed by FISH analysis using CEP probes targeting chromosomes 4,10, and 17.

Hypodiploidy and Near-Haploidy
Hypodiploidy is characterized by less than 46 chromosomes and is further subtyped into HH (40-43 chromosomes), low hypodiploidy (30-39 chromosomes), and near haploidy (25-29 chromosomes), the latter two being associated with extremely poor prognosis. 25It is seen in 1% of childhood and 3 to 4% of adult BCP-ALL.Near haploid and low hypodiploid karyotypes show monosomies of chromosomes 3,4, 7,13,15,16, and 17, while chromosomes X,14,18, and 21 show two copies. 26asked Hypodiploidy: In a proportion of patients with hypodiploidy, the hypodiploid clone can be masked through a process called endoreduplication.In these patients, the hypodiploid clone duplicates the number of chromosomes and the karyotype can reveal only metaphases derived from the endoreduplicated clone with 50 to 79 chromosomes. 27he patients are erroneously categorized as HH ALL.Masked hypodiploidy can be identified by SNP arrays, where the chromosomes with two copies showing uniparental isodisomy and chromosomes with four copies showing 2:2 allelic ratios. 28Flow-based ploidy analysis may show two peaks corresponding to the hypodiploid clone and the endoreduplicated hyperdiploid clone.Presence of characteristic pattern of gains of chromosomes also aids in identifying a masked hypodiploidy warranting further investigation.We devised a systematic cytogenetic strategy to identify masked hypodiploidy using a combination of flow ploidy, pattern of gains of chromosome on karyotype, and targeted FISH analysis directed to identify monosomies of chromosomes 3,7,15, and 17. 29

Diagnosis of Low Hypodiploidy/Near Haploidy
Diagnosis can be established by karyotyping, FISH, and SNP arrays.TP53 mutations are seen in 90% of low hypodiploid patients. 30,31

Near Triploidy (66-79 Chromosomes)
There is evidence that near triploidy represents a hidden low hyperdiploid clone. 26Once masked hypodiploidy has been ruled out, near triploidy is to be considered as an intermediate risk factor.Diagnosis rests on karyoytping, FISH, and SNP arrays.

Near Tetraploidy (84-100 Chromosomes)
Near tetraploidy is seen in 1% of childhood ALL and is more frequent in T ALL.Near tetraploidy does not carry any prognostic impact by itself. 32Once the presence of ETV6:: RUNX1, BCR::ABL1 fusions and KMT2A rearrangements have been ruled by FISH, near tetraploidy is to be considered as an intermediate risk factor.

Amplifications: Intrachromosomal Amplification of 21
iAMP21 is seen in 2% of pediatric ALL and is rare in adults. 33It is characterized by gains and losses along the long arm of chromosome 21 with RUNX1 gene being present in the common area of amplification. 34The common regions of deletions involve subtelomeric region of chromosome 21. 18,35SNP array and whole genome studies have inferred that the formation of iAMP21 involves breakage-fusionbridge cycle, resulting in amplification and formation of dicentric chromosomes and chromothripsis. 34Associated with high relapse risk, intensive therapies have improved outcomes in recent years. 36iagnosis of iAMP21: On karyotype iAMP21 is seen as a grossly abnormal chromosome 21, the diagnosis being supported by FISH analysis showing more than or equal to three copies of RUNX1 gene on the arm of the chromosome 21. 35n interphase FISH iAMP21 is defined as more than or equal three five copies of RUNX1 gene per cell.On interphase FISH care should be taken to differentiate from HH as more than or equal to five copies of RUNX1 may be seen in HH patients as well.In doubtful cases FISH targeting the subtelomeric region of chromosome 21 may help in diagnosis.SNP array analysis identifies a typical pattern of gains and losses associated with iAMP21 and is diagnostic in rare atypical cases where additional copies of RUNX1 gene may be present on other chromosomes. 37

Rearrangements
The chromosomal translocations in BCP-ALL commonly involve transcription factors, epigenetic modifiers, cytokine receptors, and tyrosine kinases.The translocations deregulate gene expression either by forming a chimeric transcript or overexpression of a gene by juxtaposition of enhancers to the partner gene.t(12;21)(p13:q22)/ETV6::RUNX1 ETV6::RUNX1 fusions are more frequent in childhood ALL and account for 25% of pediatric ALL in Western data and around 18% as per our data. 2,17,38,39It is associated with favorable outcomes.The ETV6::RUNX1 fusion is known to occur prenatally where it gives to rise to pre-leukemia state followed by secondary mutations that trigger overt leukemia. 40iagnosis: The t(12;21) is cryptic and is best identified by FISH analysis using dual-color fusion probes.The FISH approach has more advantages than the molecular RTPCR approach as the transcript expression can be low and also the FISH analysis using ETV6::RUNX1 probe additionally identifies HH, iAMP21, and other ETV6 fusions as well.
TCF3 Rearrangements: t(1;19)(q23;p13)/TCF3::PBX1 and t (17;19)(q22;p13) /TCF3::HLF1 TCF3::PBX1 fusions occurs in approximately 6% of BCP-ALL and associated with intermediate risk. 49,50The fusion protein is formed by joining the homeobox (HOX) gene PBX1 (for pre-B cell homeobox 1) on chromosome 1 with the two activation domains of the basic helix-loop-helix transcription factor TCF3 on chromosome 19 leading to transcriptional activation of PBX1.TCF3::HLF fusion is a rare genetic subtype seen in less than 1% of BCP ALL. 51Patients frequently present with disseminated intravascular coagulation, hypercalcemia, 52 low WBC counts, and absence of CD34 expression on immunophenotyping.It is associated with a dismal prognosis, despite treatment intensification and allogenic stem cell transplantation. 53iagnosis: Identified by karyotyping, FISH, and molecular methods.The translocation t(1;19) may occur either as a balanced form or an unbalanced form (only derivative 19 present), the unbalanced form being more common. 50,54ot all patients with t(1;19) identified on karyotype carry the TCF3::PBX1 transcript especially those associated with HH. 55 FISH analysis using a break-apart probe identifies these translocations accurately.The translocation t(17;19) can be identified by karyotyping and FISH.The TCF3 breakapart probe is included in our FISH panel.Patients testing positive for TCF3 rearrangement using break-apart probe are investigated using tricolor fusion probe that identifies the specific partners, that is, PBX1 and HLF1.

KMT2A Rearrangements
KMT2A rearrangements are hallmark of infant ALL with an increased prevalence in adolescents and young adults (4%) and peaking in adults (15%).KMT2A (MLL) gene can rearrange with more than 80 partners and more than 100 different translocations have been described.They are strong drivers of leukemogenesis with very few secondary alterations and are associated with poor prognosis. 56iagnosis: Best identified by FISH analysis using breakapart probes.Karyotyping identifies partners and in patients with poor chromosome morphology match metaphase FISH analysis helps in identifying partner.KMT2A rearrangements involving genes located close to the KMT2A gene on chromosome 11 (ATP5L and USP2) show a normal FISH pattern and these rearrangements are best identified using molecular techniques or RNA sequencing. 57

B-Other ALL
B-Other ALL is a heterogenous group defined by absence of all routinely assessed classifying cytogenetic abnormalities described above and are classified as intermediate risk cytogenetics.In the preceding decade, over 18 different genetic subtypes in the B-Other group have been identified, with differing treatment outcomes (►Fig.2). 14Subtypes with good outcomes are DUX4 fusions (associated with ERG deletions).Poor outcome subtypes include Ph-like ALL which may benefit from intensive therapy along with tyrosine kinase inhibitors. 43,44MEF2D and ZNF384 fusions have been reported to be associated with intermediate prognosis. 58Independent of these cytogenetic groups, somatic copy number alterations and gene mutations are also of prognostic significance.Among these, are deletions in IKZF1 (IKZF1 del ) especially when accompanied by deletions in CDKN2A/B, PAX5 and the PAR1 locus; deletions in RB1, NR3C1, BTG1; and mutations in TP53, and PAX5. 8,59le of Karyotyping and FISH in Identifying Different Subtypes of B-other BCP-ALL Karyotype is a discovery tool and serves as a screening tool to identify structural abnormalities and rearrangements which can be confirmed through FISH analysis using specific probes.
MEF2D Rearranged BCP ALL MEF2D (myocyte enhancer factor 2D)-rearranged ALL accounts for 4% of pediatric and 10% of adult ALL with a higher incidence in adolescents.It is characterized by a distinct immunophenotype (CD10 À , CD38 þ ) and is associated with a poor prognosis. 58,60,61The common fusion partner genes include BCL9 (1q21), HNRPULN1 (19q13.2),DAZAP1 (19p13.3),CSF1R (5q32),SS18(18q11.2),STAT6 (12q13.3),and FOXJ2 (12p13.3).The fusions result in increased cell growth, resistance to dexamethasone, and increase of HDAC9 expression.The most common fusion is the MEF2D::BCL9 fusion which is the result of an interstitial deletion between 1q21 and 1q22.The fusion is cryptic and cannot be identified by karyotyping.MEF2D rearrangements lead to increased HDAC9 expression, therefore amenable to histone deacetylase inhibitor treatment. 58iagnosis: The diagnosis is based on characteristic immunophenotype confirmed by FISH analysis using a MEF2D break-apart probe.3][64] The ZNF384 gene functions as a transcription factor and multiple partners have been described.The ZNF384 rearranged ALL have a distinct transcriptomic signature and are associated with aberrant expression of myeloid markers (CD13 and CD33).With a stem cell signature, the ZNF384 rearrangements have been reported in biphenotypic, mixed phenotype, and acute undifferentiated leukemia. 65iagnosis: The aberrant expression of myeloid markers provides a clue.The rearrangements are undetectable by karyotyping and are identified by FISH analysis using a ZNF384 break-apart probe.
BCR::ABL1 Like (Ph-Like ALL) The BCR::ABL1-like (Ph-like) is characterized by gene expression profile similar to BCR::ABL1 fusion positive patients but lacks the BCR::ABL1 fusions. 15,16Ph-like ALL is seen in 12% of childhood, 21% of adolescent 27% of young adult, and 20 to 24% in adults more than 40 years of age.It is a heterogeneous group consisting of gene rearrangements, copy number alterations, and mutations that activate tyrosine kinase or cytokine receptor signaling.Similar to BCR::ABL1 positive ALL, IKZF1 deletions are found in 70 to 80% of Ph-like ALLs and are associated with poor outcomes. 15he definition of Ph-like ALL is based on gene expression profile, while the cytogenetic approach to identify this entity is based on identifying CRLF2 rearrangements and identifying ABL class fusions using break-apart probes (►Fig. 3).

CRLF2 Rearranged BCP-ALL
The CRLF2 gene is located on the pseudoautosomal regions of the sex chromosomes X and Y.The two common genomic alterations resulting in CRLF2 rearrangement include t(X;14) (p22.3;q32.33)or t(Y:14)(p11.32;q32.33)and CRLF2::P2RY8 fusion resulting from 320KB interstitial deletion within the PAR1 region bringing the two genes together. 5,66,67The P2RY8::CRLF2 fusions have also been identified with other primary cytogenetic abnormalities like HH and iAMP21.CRLF2 rearrangements result in overexpression of the CRLF2 protein that can be detected by multiparametric flow cytometry.The IgH translocation places the CRLF2 gene under the impact of IGH enhancer and in CRLF2::P2RY8 fusion under the influence of promoter sequences of the P2RY8 gene.
Rearrangement of the CRLF2 gene is seen in 50% of Ph-like ALL and in half of Down syndrome-associated BCP-ALL. 68The CRLF2 rearrangements are associated with poor prognosis in non-Down syndrome pediatric and adult patients. 38,41,69iagnosis: Both the IgH::CRLF2 and P2RY8::CRLF2 are cryptic and cannot be detected on karyotype.They can be detected by FISH using a CRLF2 break-apart probe.CRLF2:: P2RY8 fusions can also be identified by detecting deletion in the PAR1 region by using multiplex ligation-based probe amplification (MLPA) or chromosomal micro arrays or SNP arrays.

ABL Class Fusions
ABL class fusions although not so frequent in BCP-ALL (3-5% of pediatric ALL, 2-3% of adult ALL) are seen in 10% of Ph-like ALL. 41,42,70The ABL class rearrangements result in fusion of the 5′ partner gene with 3′ of the kinase gene resulting in transcripts that have intact tyrosine kinase domain resulting in activation of the kinase pathway. 70The frequently involved kinase genes include ABL1, ABL2, CSF1R, PDGRFB, and PDGRFA. 69iagnosis: The fusions can be identified by RNA sequencing and multiplex PCR assays.Cytogenetically, the presence of an additional ABL1 signal on BCR::ABL1 FISH is a screening tool and hints toward the presence of the ABL1 rearrangements.Since the Ph-like ALL is associated with poor response to induction therapy and high MRD, our cytogenetic approach is based on FISH analysis using break-apart probes targeting ABL1, ABL2, CSF1R, PDGRFB, and PDGRFA in patients not in remission at end of induction or having a high MRD.Karyotype can also identify translocations involving the kinase genes that are confirmed using specific break-apart probes.

JAK Rearrangements and Mutations
Translocations resulting in rearrangement of JAK2 gene are seen in 5% of pediatric Ph-like ALL and more frequently in young adults. 69The JAK2 rearrangements result in in frame fusion of the 5′ of the partner gene with the 3′ of the JAK2 kinase gene keeping the tyrosine kinase domain intact.The JAK2 fusions can be identified by molecular techniques, RNA sequencing, visible chromosomal rearrangements involving the 9p24 loci, and FISH analysis using the break apart probe.The JAK2 mutations are frequent in CRLF2 rearranged ALL and result in activation of the JAK-STAT pathway.The mutations can be identified using Sangers sequencing.The other JAK mutations are not so common and involve the JAK1 gene.

IKZF1 Deletions and IKZF1 plus BCP ALL
IKZF1-deletions are known to have poor outcomes in ALL overall, 71 and are associated with resistance to therapy.IKZF1 deletions with co-occurring alterations in CDKN2A/2B, PAX5, and PAR1 (pseudo-autosomal region) in the absence of ERG deletions are defined as IKZF1 plus are associated with poor outcomes and high rates of treatment failure. 72he IKZF1 deleted and IKZF1 plus are commonly identified using MLPA or chromosomal microarray analysis. 12In recent times, FISH probe targeting the exon 4-7 of the IKZF1 gene has been used to identify the whole gene and intragenic deletions of the IKZF1 gene. 73Karyotyping identifies monosomy 7, deletions of short arm of chromosome 7, and dicentric translocations that result in deletion of the entire short arm of chromosome 7. Dicentric translocations between the long arm of chromosomes 7 and 9 result in deletions of the entire short arms of chromosomes 7 and 9 and are consistent with the diagnosis of IKZF1 plus.

Fig. 2
Fig. 2 Techniques available for genetic profiling of B-Other ALL.

Fig. 3
Fig. 3 Cytogenetic approach to identify Ph-like ALL with ABL1 rearrangement (A and B) and CRLF2 rearrangement (C).

Table 1
Primary cytogenetic and secondary genetic abnormalities in BCP-ALL Indian Journal of Medical and Paediatric Oncology Vol.44 No. 5/2023 © 2023.The Author(s).Cytogenetics of Acute Lymphoblastic Leukemia Dhabe et al.diagnostics laboratories is limited by high cost per test and inability to identify fusions resulting from balanced translocations.